コンテンツへスキップ
Merck

HPA014572

Sigma-Aldrich

Anti-BMP1 antibody produced in rabbit

enhanced validation

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

別名:

Anti-BMP-1, Anti-Bone Morphogenetic Protein 1 precursor, Anti-Mammalian tolloid protein, Anti-PCP, Anti-Procollagen C-proteinase, Anti-mTld

ログイン組織・契約価格を表示する


About This Item

MDL番号:
UNSPSCコード:
12352203
Human Protein Atlas Number:
NACRES:
NA.43

由来生物

rabbit

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

製品種目

Prestige Antibodies® Powered by Atlas Antibodies

形状

buffered aqueous glycerol solution

化学種の反応性

human

強化検証

orthogonal RNAseq
Learn more about Antibody Enhanced Validation

テクニック

immunohistochemistry: 1:20- 1:50

免疫原配列

DSEPLNYKDPCKAAAFLGDIALDEEDLRAFQVQQAVDLRRHTARKSSIKAAVPGNTSTPSCQSTNGQPQRGACGRWRGRSRSRRAATSRPERVWPDGVIPFVIGGNFTGS

UniProtアクセッション番号

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... BMP1(649)

詳細

BMP1 (bone morphogenetic protein 1) is a metalloproteinase belonging to the astacin family. This gene is localized to human chromosome 8p21.3, and is alternatively spliced to produce BMP1 and the longer isoform tolloid protein (TLD). This protein is produced as a proenzyme, which consists of leader peptide, a prodomain, one catalytic domain, three CUB domains, and one epidermal growth factor (EGF)-like domain.

免疫原

骨形成タンパク質1前駆体のPrEST(protein epitope signature tag)抗原リコンビナントタンパク質。

アプリケーション

Prestige抗体®は、Human Proteome Resource(HPR)プロジェクト(www.proteinatlas.org)によって開発・実証されたAtlas抗体です。抗体はすべて、数百の正常組織・疾病組織に対する免疫組織染色試験を行っています。これらの染色画像はHuman Protein Atlas(HPA)サイトで[Image Gallery]リンクをクリックするとご覧いただけます。さらに、ほとんどのPrestige抗体はプロテインアレイおよびウェスタンブロッティングの試験を行っています。試験のプロトコールおよびPrestige抗体、HPAに関する情報はsigma.com/prestigeをご覧ください。

生物化学的/生理学的作用

BMP1 (bone morphogenetic protein 1) processes the naïve form of extracellular matrix (ECM) proteins to the mature form, and therefore, are involved in morphogenesis. It also controls the processing of multiple growth factors such as, TGFβ, BMP2, BMP4 and GFD (growth differentiation factor) 8. It facilitates the conversion of bone marrow mesenchymal stem cells to mineralized bone cells. Thus, it enhances bone repair. It makes up the BMP1/TLD-like (tolloid-like) complex, which also includes TLD, tolloid-like protein 1 and tolloid-like protein 2. It is involved in the processing of procollagen I C-terminal propeptide (PICP), type II, type III, and type V procollagen and lysyl oxidase zymogen. Mutation in this gene is linked to autosomal recessive osteogenesis imperfecta. During embryogenesis, it facilitates the binding of BMPs to cognate receptors by degrading the BMP-antagonist chordin.

特徴および利点

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

関連事項

Corresponding Antigen APREST72700

物理的形状

PBS溶液(pH 7.2, 40%グリセロールおよび0.02%アジ化ナトリウム含有)。

法的情報

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 製品選択ツール.

保管分類コード

10 - Combustible liquids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

HPA014572-25UL:
HPA014572-100UL:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Ivana Kovacevic Vojtusek et al.
Diagnostics (Basel, Switzerland), 12(3) (2022-03-26)
We have previously shown that metzincin protease ADAMTS-4 accompanies renal fibrogenesis, as it appears in the blood of hemodialysis patients. Native kidney (NKB) and kidney transplant (TXCI) biopsy samples as well as plasma from patients with various stages of CKD
Víctor Martínez-Glez et al.
Human mutation, 33(2), 343-350 (2011-11-05)
Herein, we have studied a consanguineous Egyptian family with two children diagnosed with severe autosomal recessive osteogenesis imperfecta (AR-OI) and a large umbilical hernia. Homozygosity mapping in this family showed lack of linkage to any of the previously known AR-OI
Mat Leighton et al.
The Journal of biological chemistry, 278(20), 18478-18484 (2003-03-15)
Bone morphogenetic protein (BMP)-1 is a zinc-dependent metalloproteinase that cleaves a variety of extracellular matrix substrates, including type I procollagen. Little is known about the site of action of BMP-1, although the extracellular matrix seems likely to be it. BMP-1
Lovorka Grgurevic et al.
Biochemical and biophysical research communications, 408(1), 25-31 (2011-04-02)
Members of the astacin family of metalloproteinases such as human bone morphogenetic protein 1 (BMP-1) regulate morphogenesis by processing precursors to mature functional extracellular matrix (ECM) proteins and several growth factors including TGFβ, BMP2, BMP4 and GFD8. We have recently
Yung-Yu Hsieh et al.
BMC cancer, 18(1), 508-508 (2018-05-04)
Gastric cancer is the eighth most common cancer in Taiwan, with a 40% 5-year survival rate. Approximately 40% of patients are refractory to chemotherapy. Currently, the anti-HER2 therapy is the only clinically employed targeted therapy. However, only 7% patients in

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)